Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Moderna (Nasdaq: MRNA) will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 p.m. ET / 4:30 p.m. PT. A live webcast will be available under "Events and Presentations" in the Investors section at investors.modernatx.com. A replay will be archived on Moderna's website for at least 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – MRNA
In the Dec 17 session, MRNA gained 2.07%, reflecting a moderate positive market reaction. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Regulatory opinion | Positive | +1.6% | EMA committee issued positive opinion for mNEXSPIKE COVID-19 vaccine. |
| Nov 20 | Strategy update | Positive | -7.5% | Analyst Day outlined growth strategy, cost reductions, and pipeline plans. |
| Nov 20 | Financing facility | Positive | -7.5% | Announced up to $1.5B non-dilutive term loan facility with Ares. |
| Nov 19 | Manufacturing expansion | Positive | -3.0% | Onshoring U.S. Drug Product manufacturing with >$140M investment. |
| Nov 18 | Conference appearance | Neutral | +0.7% | Announced presentation at Piper Sandler healthcare conference with webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news includes positive regulatory and strategy updates plus neutral conference appearances, with price reactions mixed: some positive regulatory outcomes saw modest gains, while strategic and financing updates sometimes coincided with declines.
Over the last few months, Moderna reported multiple notable events, including a positive EMA opinion for mNEXSPIKE on Dec 15 with a +1.56% reaction, strategy and financing updates on Nov 20 tied to an Analyst Day and a $1.5B term loan, and U.S. manufacturing expansion on Nov 19. It also announced another conference appearance on Nov 18 with a small gain. Today’s J.P. Morgan conference notice fits into this pattern of frequent investor and strategic communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT.
A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.
A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire